Glucagon Application Scope: A Descriptive Summary of Its Uses
Abstract: Glucagon, a 29-amino acid peptide hormone, is primarily indicated for severe hypoglycemia and as a diagnostic aid in gastrointestinal imaging. Its application scope extends to peptide-based therapeutics, where it demonstrates rapid onset and high efficacy. Market trends show a CAGR of 6.8% (2024-2030), driven by diabetes prevalence and novel formulations. Compared to analogs like dasiglucagon, native glucagon offers lower cost but shorter stability. Key technical advantages include parenteral administration and glycogenolysis activation; limitations involve reconstitution complexity and hyperglycemic rebound. Brand analysis highlights Eli Lilly’s Glucagon Kit vs. Xeris’s Gvoke, with the latter offering ready-to-use, room-temperature storage. Product parameters: 1 mg/mL, pH 2.5-3.5, stability 24 months at 2-8°C. Selection criteria prioritize stability, delivery device, and regulatory certifications (FDA, EMA). Logistics require cold chain compliance (2-8°C) and lyophilized powder transport. Industry data indicates 78% market share for hypoglycemia rescue, with emerging cardiac applications.